Are statins anti-inflammatory? issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation

Current Cardiology Reports

Volumn 2, Issue 4, 2000, Pages 269-273

  Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART INFARCTION; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

C-REACTIVE PROTEIN; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MYOCARDIAL INFARCTION; PRAVASTATIN; RANDOMIZED CONTROLLED TRIALS;

EID: 0034218523     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0080-8     Document Type: Review

References (27)

1. Sacks FM, Pfeffer MA, Moye LA, et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
2. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
3. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
4. Shepard J, Cobb SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
5. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622.
6. Rosenson RS, Tangney CC: Anti-atherothrombotic properties of statins. Implications for cardiovascular event reduction. JAMA 1998, 279:1643-1650.
7. Aikawa M, Rabkin E, Okada Y, et al. : Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998, 97:2433-2444.
8. Aikawa M, Voglic SJ, Sugiyama S, et al. : Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999, 100:1215-1222.
9. Shiomi M, Ito T, Tsukada T, et al. : Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995, 15:1938-1944.
10. Williams JK, Sukhova GK, Herrington DM, Libby P: Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998, 31:684-691.
11. Shiomi M, Ito T: Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. Br J Pharmacol 1999, 126:961-968.
12. Bellosta S, Via D, Canavesi M, et al. : HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998, 18:1671-1678.
13. Ross R: Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
14. Ridker PM, Cushman M, Stampfer MJ, et al. : Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
15. Ridker PM, Buring JE, Shih J, et al. : Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
16. Tracy RP, Lemaitre RN, Psaty BM, et al. : Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997, 17:1121-1127.
17. Kuller LH, Tracy RP, Shaten J, Meilahn EN, for the MRFIT Research Group: Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiology 1996, 144:537-547.
18. Koenig W, Sund M, Froelich M, et al. : C-reactive protein, a sensitive marker of inflammation, predicts future risk of coroanry heart disease in initially healthy middle-aged men: results from the MONICA Augsberg Cohort Study, 1984 to 1992. Circulation 1999, 99:237-242.
19. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
20. Ridker PM, Glynn RJ, Hennekens CH: C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998, 97:2007-2011.
21. Harris TB, Ferrucci L, Tracy RP, et al. : Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
22. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
23. Hwang SJ, Ballantyne CM, Sharrett AR, et al. : Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997, 96:4219-4225.
24. Ridker PM, Hennekens CH, Roitman-Johnson B, et al. : Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998, 351:88-92.
25. Ridker PM. Sacks F, Pfeffer MP, et al. : for the Cholesterol and Recurrent Events (CARE) Investigators: Elevation of tumor necrosis factor-a and increased risk of recurrent coronary events following myocardial infarction. Circulation 2000, 101:2149-2153.
26. Ridker PM, Rifai N, Pfeffer MA, et al. : for the Cholesterol and ecurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998, 98:839-844.
27. Ridker PM, Rifai N, Pfeffer M, et al. : Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.